Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer.
Gastrin-releasing peptide (GRP), the mammalian bombesin (BN), appears to be involved in the growth of several neoplasms. BN/GRP receptors (BN/GRP-Rs) are expressed in a variety of cancer cells and have limited distribution in normal human tissue. Thus inhibition of BN/GRP-Rs represents an attractive target for pharmacological treatment of some human malignancies. This review will focus on intracellular signaling pathways which have been characterized to mediate BN/GRP-dependent receptor biological effects as well as on various approaches to target BN/GRP-Rs for therapeutic and diagnostic interventions in human malignancies.
Hohla
Florian
F
IIIrd Medicine with Haematology, Oncology, Rheumatology and Infectiology, Private Medical University of Salzburg, Austria.
Schally
Andrew V
AV
D001839:Bombesin / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000378:metabolism; D019886:Gastrin-Releasing Peptide / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D018004:Receptors, Bombesin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction
D018004:Receptors, Bombesin; D019886:Gastrin-Releasing Peptide; D001839:Bombesin